SEC Form 4 · accession 0001636050-17-000033
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Machado
Director · 10% Owner
Period of report
Jul 17, 2017
Accepted (ET)
Jul 19, 2017 · 12:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $23.67 | Jul 17, 2017 | A | 70,000 | A | — | Jul 16, 2027 | Common Shares | 70,000 | 70,000 | D |
Explanation of responses
- F1This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of June 15, 2017, the date the Reporting Person commenced his service as a member of the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney